MedTrace Logo

Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer

NCT03146377 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-05-09

No results posted yet for this study

Summary

This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with refractory metastatic colorectal cancer. Clinical data from patients diagnosed with colorectal cancer will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of medical oncology of the Department of Medicine, Queen Mary Hospital.

Conditions

Interventions

DRUG

Capecitabine

1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

DRUG

Oxaliplatin

85 mg/m2 IV on day 1 of a 2-week cycle

DRUG

Irinotecan

165 mg/m2 IV on day 1 of a 2-week cycle

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Thomas Yau, MD · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146377 on ClinicalTrials.gov